title: [Value of immunohistochemical staining with mutation-specific antibodies in detecting EGFR mutations: a meta-analysis].
abstract: BACKGROUND
  It has been proven that epidermal growth factor receptor (EGFR) mutation is the most important predictive factor for determining the effect of EGFR tyrosine kinase inhibitors (TKIs) applied to non-small cell lung cancer (NSCLC) patients. The patients with EGFR mutations response better to TKIs. To detect EGFR mutation has been particularly essential to select first-line treatment for lung cancer patients. To research and analyze the sensitivity and specificity of immunohistochemistry (IHC) using mutation specific antibodies in detecting EGFR mutations compared with DNA sequencing, and further evaluate the accuracy and clinical application value of IHC.
  
  
  METHODS
  All required articles in Pubmed database were searched. The deadline of retrieval was March 26, 2013. Then further screening the articles based on the inclusion and exclusion criteria. Meta analysis of diagnostic test was applied to analyze the sensitivity and specificity of IHC compared with DNA sequencing for the detection of EGFR mutations.
  
  
  RESULTS
  Ten articles were included in the meta analysis, there were 1,679 samples in L858R group and 1,041 samples in E746-A750del group. The DOR were 225.17 (95%CI: 55.67-910.69) and 267.16 (95%CI: 132.45-538.88) respectively; the AUC of SROC were 0.948,4 (SEAUC=0.014,4) and 0.981,3 (SEAUC=0.009,9) respectively; the Q values were 0.888,3 (SEQ*=0.019,2) and 0.939,7 (SEQ*=0.019,1) respectively.
  
  
  CONCLUSIONS
  The specificity and sensitivity of IHC method using these two mutation-specific antibodies were relatively high. As a screening method for EGFR mutations, the IHC with mutation specific antibodies is of clinical value.
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Ma
authors.affiliation: Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China;Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Diansheng
authors.initials: D
authors.lastname: Zhong
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Ning
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Xiao
mesh_terms: D000906:Antibodies / Q000032:analysis; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D012680:Sensitivity and Specificity; D013194:Staining and Labeling / Q000379:methods*
chemical_list: D000906:Antibodies; D066246:ErbB Receptors